ArticleLung India : official organ of Indian Chest Society2025
Low occurrence of pulmonary lophomoniasis among cigarette smokers: An analysis of risk factors based on registry data.
Article in Lung India : official organ of Indian Chest Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLophomonas blattarum is an emerging protozoan agent that mainly causes pulmonary lophomoniasis. Given that cigarette smokers are predisposed to various diseases while some conditions are less common among them, the current study aimed to compare the relationship between smoking status and the prevalence of pulmonary lophomoniasis in patients registered at the Iranian National Registry Center for Lophomoniasis (INRCL). Additionally, we examined common risk factors associated with Lophomonas infection among these registered subjects. MATERIALS AND
methodsThis descriptive-analytical cross-sectional registry-based study was conducted on 600 registered subjects through microscopic examination (wet mount smears) and conventional polymerase chain reaction assay between 2021 and 2023. We analysed the smoking status and smoking intensity of 135 Lophomonas-positive patients and 465 Lophomonas-negative patients who were referred to the INRCL. Baseline data were collected from participants using a questionnaire.
resultsOur results showed the prevalence of Lophomonas infection among enrolled subjects was estimated to be 22.5% (135/600). Also, we studied 135 Lophomonas positive patients (male = 92, female = 43). Furthermore, most patients testing positive for Lophomonas (74.8%; 101/135) also had at least one comorbidity condition. Our findings showed a statistically significant occurrence of Lophomonas infection among non-smokers (70.4%; n = 95), in contrast to smokers (29.6%; n = 40) (P = 0.001). Correspondingly, among the 40 Lophomonas-positive smokers, the majority (62.5%) were classified as light smokers. Moreover, based on the multiple logistic regressions, Lophomonas infection was 2.123, 3.142, and 2.353 times higher in men compared to women, patients aged 51-70 years compared to other age groups, and non-smokers compared to cigarette smokers, respectively (P = 0.001).
conclusionOur findings reveal that Lophomonas infection is significantly lower among cigarette smokers compared to nonsmokers. Our data shed light on a new hypothesis about lophomoniasis among smokers. Further research is needed to assess the role of smoking in the pathophysiology of lophomoniasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.